Latest Conference Articles

Patient-Provider Surveys Elucidate Biosimilar Switching Process in Oncology

Tony Hagen

December 13 2021

After a switch to a biosimilar, patients and their oncologists may not always agree on how well the switch was described or whether the patient felt involved.

Ontruzant Biosimilar Demonstrates Equivalence to Herceptin in 5-Year Study

Tony Hagen

December 9 2021

The trial included "drifted" (nonstandard) reference product, forcing a stratified analysis to yield relevant data.

EirGenix Trastuzumab Biosimilar Candidate Demonstrates Equivalence in HER2-Positive Breast Cancer

Tony Hagen

December 8 2021

A trastuzumab biosimilar candidate demonstrated equivalence to Herceptin in patients with early-stage human epidermal growth factor receptor 2 (HER2)–breast cancer.

Biosimilars Roundup: November Was Dominated by Legislative and Regulatory News

November 30 2021

Regulators are at work clarifying biosimilar guidance and on Capitol Hill, a battle is raging over reforms that could help or hurt biosimilar advancement.

Biosimilar Industry Critiques Biden's Drug Pricing Reforms

Tony Hagen

November 29 2021

Specialty tiers for biosimilars and reforms that address the proliferation of poor-quality patents would help lower costs and improve access, biosimilar industry veterans said.

COA Study: Biosimilars Have Broadened Patient Access in Oncology

Tony Hagen

November 13 2021

Kathy Oubre, MS, a cochair of the biosimilars committee of the Community Oncology Alliance (COA), explains findings from a broad study of biosimilar use in oncology practices.

FDA Official Addresses Unanswered Questions About Interchangeable Biosimilars

Tony Hagen

November 10 2021

Sarah Yim, MD, provided a point-by-point overview of the FDA's efforts to clarify the role of the interchangeable biosimilar designation, improve communication with manufacturers, and pay for biosimilar regulatory reviews.

Expert Discusses Chinese Biosimilar Business Prospects in the European Union

November 9 2021

A consultant who specializes in helping Chinese biosimilar companies market their products in the European Union discusses the challenges and opportunities.

FDA’s Woodcock Says Agency Has Resumed Normal Review Pace for Biosimilars, Generics

Tony Hagen

November 8 2021

Janet Woodcock, MD, acting commissioner of the FDA, said the agency is meeting with biosimilar developers for biosimilars for 46 reference products.

IPD Analytics Executive Offers Perspective on Biosimilar Uptake and Policy

Tony Hagen

November 1 2021

Payers have moved from toe-in-the-water biosimilar policies to aggressive management, contributing to much more robust savings in recent years, according to Leslie Fish, RPh, PharmD, vice president of pharmacy at IPD Analytics.